Tag Archives: Venture Capital

BIO-Europe Spring Opening Remarks

Chart

BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Biotech Hall of Fame: Interview with Biotech’s First Investment Banker

Biotech Hall of Fame

Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does happen once or twice a year on average. In the headlines last week, was the largest triple digit VC round in years – the $160M in venture capital funding for Intarcia. With the simultaneous debt financing of $50M, the total funding round was $210M. Behind the deal were existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock, plus Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

It Takes a Village: The New Pharma-VC Model for Biotech Investing

bif-hall

High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. BIO Executive Vice President Alan Eisenberg moderated It Takes a Village: The New Pharma-VC Model for Biotech Investing, a panel discussion about these new funding models, during the opening plenary session at the 2012 BIO Investor Forum. In the past, venture capital could Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Europe Spring 2012 – Opening Remarks

For Monday’s Opening Remarks at BIO Europe Spring 2012, I covered the following topics: Public market performance in the US vs other sectors Private funding environment. Drug pipeline deal volume. For a copy of the slides, they can be found here.

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,